Novonix (ASX:NVX) raises A$20.7m at a 33% discount after the C-sample win

Bell Potter cleared the book at A$0.16, telling holders what the Riverside capacity build really costs

Novonix (ASX:NVX) has placed A$20.7 million with institutional and sophisticated investors at A$0.16 a share, a 33.3% discount to the last close of A$0.24. A non-underwritten share purchase plan at the same price could add another A$3.0 million if eligible retail holders fill it.

Bell Potter ran the book and pockets a 5% fee. Proceeds, according to management, fund capital expenditure for production capacity and forecast customer demand at the Riverside facility in Chattanooga.

The timing is what makes this raise interesting. The C-sample for Panasonic Energy was only just delivered, meant to be the data point that restored credibility after a year of slipped milestones and a lost Stellantis offtake. Investors who bought the recovery narrative have now been asked to back it with fresh capital at a deep discount.

The market knew capex was coming. The question was whether Novonix could find a way to fund it that did not punish the share price. Today’s terms suggest the answer is no.

A 33% discount tells you what institutions thought of the price

A 31.2% discount to the five-day VWAP is not a normal placement. It is the kind of clearing level Bell Potter sets when institutions need margin of safety to absorb both operational risk and the overhang of the SPP that follows.

Our concern is that the discount sets a new reference price the market will anchor to. Stock that was trading at A$0.24 on 15 June now has a A$0.16 print stamped on the register, and the SPP requires an ASX waiver to issue below the 20% discount cap.

The capex story is what the C-sample bought

Management has been signposting a tenfold capacity expansion by 2035, with mass production for Panasonic still guided to commence in the second half of 2027. That target requires equipment, working capital and qualification spend ahead of any meaningful revenue.

The C-sample delivery was the operational green light. This raise is the financial green light. They were always going to arrive together, because no board signs off on a deep-discount placement without a credible operational reason to defend it.

Worth noting the announcement does not break down how the A$23.7 million potential gross splits across Riverside, the broader anode build and general working capital. For a raise of this size at this dilution, that lack of specificity is the thing holders should ask about.

Dilution math meets a thinning board layer

Novonix is using its full 15% Listing Rule 7.1 capacity, roughly 129 million shares. That is a meaningful slug of new paper hitting a register already battered by Stellantis, the CFO departure and the Panasonic slip.

The announcement was authorised by Chairman Ron Edmonds, still wearing the interim CFO hat after Robert Long left in July. A raise of this scale signed off by an interim finance leader is not ideal optics. We would want a permanent CFO appointment alongside, or shortly after, a transaction this size.

The Investors Takeaway for Novonix

The C-sample restored some operational credibility. This raise puts a price tag on that credibility, and it is a steep one for existing holders. Riverside now has the capital it needs to keep moving toward 2H 2027, but the cost was a re-rate lower on the share register before the offtake economics have been wired in.

We think the next twelve months hinge on two things. Whether Panasonic’s validation work converts the C-sample into a binding offtake, and whether a permanent CFO arrives with a clear capex roadmap that does not require a second raise inside FY27. Investors can read our previous coverage of the C-sample milestone at stocksdownunder.